866-997-4948(US-Canada Toll Free)

Relapsed Multiple Myeloma - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Oncology

No. of Pages : 321 Pages

This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Relapsed Multiple Myeloma
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Relapsed Multiple Myeloma and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Relapsed Multiple Myeloma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Relapsed Multiple Myeloma pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Relapsed Multiple Myeloma
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Relapsed Multiple Myeloma pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Content

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Relapsed Multiple Myeloma Overview 8
Therapeutics Development 9
Pipeline Products for Relapsed Multiple Myeloma - Overview 9
Pipeline Products for Relapsed Multiple Myeloma - Comparative Analysis 10
Relapsed Multiple Myeloma - Therapeutics under Development by Companies 11
Relapsed Multiple Myeloma - Therapeutics under Investigation by Universities/Institutes 15
Relapsed Multiple Myeloma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Relapsed Multiple Myeloma - Products under Development by Companies 18
Relapsed Multiple Myeloma - Products under Investigation by Universities/Institutes 21
Relapsed Multiple Myeloma - Companies Involved in Therapeutics Development 22
Bristol-Myers Squibb Company 22
Johnson & Johnson 23
Kyowa Hakko Kirin Co., Ltd. 24
Sanofi 25
Eli Lilly and Company 26
GlaxoSmithKline plc 27
Genentech, Inc. 28
Piramal Enterprises Limited 29
Prolexys Pharmaceuticals, Inc. 30
Millennium Pharmaceuticals, Inc. 31
Novartis AG 32
Astellas Pharma Inc. 33
Exelixis, Inc. 34
Celgene Corporation 35
Onyx Pharmaceuticals, Inc. 36
Incyte Corporation 37
AEterna Zentaris Inc. 38
Oncolytics Biotech Inc. 39
Pharmacyclics, Inc. 40
Array BioPharma Inc. 41
MorphoSys AG 42
Senesco Technologies, Inc. 43
Threshold Pharmaceuticals, Inc. 44
Synta Pharmaceuticals Corp. 45
Acceleron Pharma, Inc. 46
Altor BioScience Corporation 47
Arno Therapeutics, Inc. 48
Stemline Therapeutics, Inc. 49
Noxxon Pharma AG 50
Acetylon Pharmaceuticals, Inc. 51
Pharma Mar, S.A. 52
Janssen Biotech, Inc. 53
AbbVie Inc. 54
Oncopeptides AB 55
Senhwa Biosciences 56
Relapsed Multiple Myeloma - Therapeutics Assessment 57
Assessment by Monotherapy Products 57
Assessment by Combination Products 58
Assessment by Target 59
Assessment by Mechanism of Action 63
Assessment by Route of Administration 67
Assessment by Molecule Type 69
Drug Profiles 71
ixazomib citrate - Drug Profile 71
daratumumab - Drug Profile 73
panobinostat - Drug Profile 75
carfilzomib - Drug Profile 81
elotuzumab - Drug Profile 84
plitidepsin - Drug Profile 86
bendamustine - Drug Profile 88
ibrutinib - Drug Profile 90
AR-42 - Drug Profile 94
ruxolitinib phosphate - Drug Profile 96
ARRY-520 - Drug Profile 100
ALT-801 - Drug Profile 102
NOX-A-12 - Drug Profile 104
chloroquine + [bortezomib] + [cyclophosphamide] - Drug Profile 106
Melflufen - Drug Profile 107
Circularly Permuted TRAIL - Drug Profile 109
alisertib - Drug Profile 110
linsitinib - Drug Profile 113
PRLX-93936 - Drug Profile 115
carfilzomib - Drug Profile 117
oprozomib - Drug Profile 120
cabozantinib (s)-malate - Drug Profile 122
SNS-01T - Drug Profile 125
SL-401 - Drug Profile 127
TH-302 - Drug Profile 129
P-276 - Drug Profile 136
MOR-202 - Drug Profile 138
KW-2478 - Drug Profile 140
luminespib - Drug Profile 141
plerixafor - Drug Profile 144
ricolinostat - Drug Profile 146
LY-2812176 - Drug Profile 148
perifosine - Drug Profile 150
tabalumab - Drug Profile 154
BMS-833923 - Drug Profile 156
dalantercept - Drug Profile 158
SAR-650984 - Drug Profile 160
dasatinib - Drug Profile 161
ganetespib - Drug Profile 164
pelareorep - Drug Profile 168
ulocuplumab - Drug Profile 172
tipifarnib - Drug Profile 173
veliparib - Drug Profile 175
silmitasertib - Drug Profile 177
quisinostat - Drug Profile 179
pomalidomide - Drug Profile 181
afuresertib - Drug Profile 184
MV-NIS Vaccine - Drug Profile 186
venetoclax - Drug Profile 188
RG-7598 - Drug Profile 191
LGH-447 - Drug Profile 193
hydroxychloroquine + sirolimus - Drug Profile 194
GSK-2857916 - Drug Profile 195
Relapsed Multiple Myeloma - Recent Pipeline Updates 196
Relapsed Multiple Myeloma - Dormant Projects 302
Relapsed Multiple Myeloma - Discontinued Products 303
Relapsed Multiple Myeloma - Product Development Milestones 304
Featured News & Press Releases 304

Appendix 316
Methodology 316
Coverage 316
Secondary Research 316
Primary Research 316
Expert Panel Validation 316
Contact Us 317
Disclaimer 317

List of Table


Number of Products under Development for Relapsed Multiple Myeloma, H1 2014 13
Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 16
Number of Products under Development by Companies, H1 2014 (Contd..1) 17
Number of Products under Development by Companies, H1 2014 (Contd..2) 18
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Late Stage Development, H1 2014 20
Comparative Analysis by Clinical Stage Development, H1 2014 21
Products under Development by Companies, H1 2014 22
Products under Development by Companies, H1 2014 (Contd..1) 23
Products under Development by Companies, H1 2014 (Contd..2) 24
Products under Investigation by Universities/Institutes, H1 2014 25
Relapsed Multiple Myeloma - Pipeline by Bristol-Myers Squibb Company, H1 2014 26
Relapsed Multiple Myeloma - Pipeline by Johnson & Johnson, H1 2014 27
Relapsed Multiple Myeloma - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2014 28
Relapsed Multiple Myeloma - Pipeline by Sanofi, H1 2014 29
Relapsed Multiple Myeloma - Pipeline by Eli Lilly and Company, H1 2014 30
Relapsed Multiple Myeloma - Pipeline by GlaxoSmithKline plc, H1 2014 31
Relapsed Multiple Myeloma - Pipeline by Genentech, Inc., H1 2014 32
Relapsed Multiple Myeloma - Pipeline by Piramal Enterprises Limited, H1 2014 33
Relapsed Multiple Myeloma - Pipeline by Prolexys Pharmaceuticals, Inc., H1 2014 34
Relapsed Multiple Myeloma - Pipeline by Millennium Pharmaceuticals, Inc., H1 2014 35
Relapsed Multiple Myeloma - Pipeline by Novartis AG, H1 2014 36
Relapsed Multiple Myeloma - Pipeline by Astellas Pharma Inc., H1 2014 37
Relapsed Multiple Myeloma - Pipeline by Exelixis, Inc., H1 2014 38
Relapsed Multiple Myeloma - Pipeline by Celgene Corporation, H1 2014 39
Relapsed Multiple Myeloma - Pipeline by Onyx Pharmaceuticals, Inc., H1 2014 40
Relapsed Multiple Myeloma - Pipeline by Incyte Corporation, H1 2014 41
Relapsed Multiple Myeloma - Pipeline by AEterna Zentaris Inc., H1 2014 42
Relapsed Multiple Myeloma - Pipeline by Oncolytics Biotech Inc., H1 2014 43
Relapsed Multiple Myeloma - Pipeline by Pharmacyclics, Inc., H1 2014 44
Relapsed Multiple Myeloma - Pipeline by Array BioPharma Inc., H1 2014 45
Relapsed Multiple Myeloma - Pipeline by Array MorphoSys AG, H1 2014 46
Relapsed Multiple Myeloma - Pipeline by Array Senesco Technologies, Inc., H1 2014 47
Relapsed Multiple Myeloma - Pipeline by Threshold Pharmaceuticals, Inc., H1 2014 48
Relapsed Multiple Myeloma - Pipeline by Synta Pharmaceuticals Corp., H1 2014 49
Relapsed Multiple Myeloma - Pipeline by Acceleron Pharma, Inc., H1 2014 50
Relapsed Multiple Myeloma - Pipeline by Altor BioScience Corporation, H1 2014 51
Relapsed Multiple Myeloma - Pipeline by Arno Therapeutics, Inc., H1 2014 52
Relapsed Multiple Myeloma - Pipeline by Noxxon Pharma AG, H1 2014 54
Relapsed Multiple Myeloma - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2014 55
Relapsed Multiple Myeloma - Pipeline by Pharma Mar, S.A., H1 2014 56
Relapsed Multiple Myeloma - Pipeline by Janssen Biotech, Inc., H1 2014 57
Relapsed Multiple Myeloma - Pipeline by AbbVie Inc., H1 2014 58
Relapsed Multiple Myeloma - Pipeline by Oncopeptides AB, H1 2014 59
Relapsed Multiple Myeloma - Pipeline by Senhwa Biosciences, H1 2014 60
Assessment by Monotherapy Products, H1 2014 61
Assessment by Combination Products, H1 2014 62
Number of Products by Stage and Target, H1 2014 65
Number of Products by Stage and Mechanism of Action, H1 2014 69
Number of Products by Stage and Route of Administration, H1 2014 72
Number of Products by Stage and Molecule Type, H1 2014 74
Relapsed Multiple Myeloma Therapeutics - Recent Pipeline Updates, H1 2014 200
Relapsed Multiple Myeloma - Dormant Projects, H1 2014 306
Relapsed Multiple Myeloma - Discontinued Products, H1 2014 307

List of Chart


Number of Products under Development for Relapsed Multiple Myeloma, H1 2014 13
Number of Products under Development for Relapsed Multiple Myeloma - Comparative Analysis, H1 2014 14
Number of Products under Development by Companies, H1 2014 15
Number of Products under Investigation by Universities/Institutes, H1 2014 19
Comparative Analysis by Clinical Stage Development, H1 2014 21
Assessment by Monotherapy Products, H1 2014 61
Assessment by Combination Products, H1 2014 62
Number of Products by Top 10 Target, H1 2014 63
Number of Products by Stage and Top 10 Target, H1 2014 64
Number of Products by Top 10 Mechanism of Action, H1 2014 67
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 68
Number of Products by Top 10 Route of Administration, H1 2014 71
Number of Products by Stage and Top 10 Route of Administration, H1 2014 72
Number of Products by Top 10 Molecule Type, H1 2014 73
Number of Products by Stage and Top 10 Molecule Type, H1 2014 74

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *